Randomized, controlled trial of Rybelsus (semaglutide) among adults with AUD
The purpose of this research study is to determine if the study medication, Rybelsus (semaglutide), decreases craving for alcohol and helps people with Alcohol Use Disorder to reduce drinking.
You will be randomly assigned to one of two groups. You will have a 50% (1 in 2) chance of receiving semaglutide and a 50% chance of receiving placebo. This is a double-blind study, which means neither you nor the study investigator will make the choice to which group you are assigned, and neither will know what group you are in. There are 8 study visits over about 11 weeks, including weekly study visits for 7 weeks, plus a follow-up phone call about two weeks after the last study visit. Compensation is provided for participation.More
- Age 21 or older - Drink regularly and meet criteria for Alcohol Use Disorder (AUD) - Interested in reducing or stopping your alcohol use
Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
University of Colorado Hospital
Joseph Schacht, PhD
Protocol Number: 23-0261
More information available at ClinicalTrials.gov: NCT05892432
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers